Kyverna Therapeutics, Inc. (KYTX)
7.66
-0.19
(-2.42%)
USD |
NASDAQ |
Jun 10, 16:00
7.645
-0.02
(-0.20%)
After-Hours: 20:00
Kyverna Therapeutics Shareholders Equity (Quarterly) : 195.58M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 195.58M |
| December 31, 2025 | 232.28M |
| September 30, 2025 | 151.95M |
| June 30, 2025 | 184.38M |
| March 31, 2025 | 224.01M |
| December 31, 2024 | 266.59M |
| September 30, 2024 | 302.71M |
| Date | Value |
|---|---|
| June 30, 2024 | 333.51M |
| March 31, 2024 | 360.99M |
| December 31, 2023 | 49.18M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 46.68M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| X4 Pharmaceuticals, Inc. | 168.45M |
| Arrowhead Pharmaceuticals, Inc. | 613.98M |
| Oncolytics Biotech, Inc. | -5.13M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.505B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 257.02M |
| Total Liabilities (Quarterly) | 61.44M |
| Debt to Equity Ratio | 0.1726 |
| Current Ratio | 8.146 |
| Net Debt Paydown Yield | -0.98% |